205 results about "Uricacidemia" patented technology

The invention relates to application of a stilbene derivative and pharmaceutically acceptable salts thereof to preparation of medicines or health-care products for preventing and / or treating hyperuricemia, and acute gout, chronic gout, gouty arthritis, gout attack, uric acid nephrolithiasis and gouty nephropathy caused by the hyperuricemia. The stilbene derivative is used as an active component for preparing the medicines for treating the hyperuricemia, can reduce the concentration of uric acid in blood, has a significant effect on treatment of the hyperuricemia, does not have toxic or side effects and has good safety.

The invention relates to Febuxostat and a drug combination thereof, wherein the Febuxostat is Febuxostat crystal, belonging to monoclinic system, the space group of the crystal is P2 (1), and cell parameters comprise a=4.7179 (9), b=17.813 (4), c=10.690 (2), alpha=gamma=90 degrees, and beta=99.20 (3) degrees; and the cell volume is 886.8(3) <3>. In addition, the invention also relates to a drug composition containing the Febuxostat crystal and a preparation method of the crystal, and simultaneously the invention further discloses application of the Febuxostat crystal in treating hyperuricemia comprising primary and secondary hyperuricemia, acute and chronic gout, gouty arthritis, gouty nephropathy and renal calculus which are caused by the hyperuricemia.

The invention discloses lactobacillus gasseri and application thereof in relieving and treating hyperuricemia, and belongs to the technical field of microorganisms. According to the lactobacillus gasseri CCFM1133 disclosed by the invention, the serum uric acid level of hyperuricemia mice and the xanthine oxidase (XOD) activity of serum and a liver can be reduced, and the occurrence of hyperuricemia and gout is reduced; the blood glucose and serum triglyceride (TG) level of a patient with hyperuricemia can be regulated, and the activity of liver catalase (CAT) and glutathione peroxidase (GSH-Px) is improved; expression of ileum ABCG2 is improved, and excretion of intestinal uric acid is promoted; and the intestinal short-chain fatty acid level is improved, and the health is promoted. The lactobacillus gasseri CCFM1133 disclosed by the invention can be used for preparing foods, functional foods or medicines, and has a wide application prospect.

The invention relates to a medicinal composition for treating hyperuricemia, which comprises Febuxostat or derivate thereof, benzbromarone and a pharmaceutically acceptable medicinal carrier, whereinthe ratio in weight portion of the Febuxostat or derivate thereof to the benzbromarone to the pharmaceutically acceptable medicinal carrier is 1:1-4:0.5-100. The medicinal composition can provide extremely beneficial effects of treating the hyperuricemia. Pharmacological tests prove that the medicinal composition has obviously synergistic action, can quickly reduce the concentration of purine trione in blood serum, remarkably improves effect of treating the hyperuricemia, greatly reduces medicament dosage of single component simultaneously, and effectively reduces toxic and side effect of medicament.

Provided is a pyridine derivative represented by formula (I), a prodrug thereof, a pharmaceutically acceptable salt of the pyridine derivative or the prodrug, or a solvate of the pyridine derivative, the prodrug or the pharmaceutically acceptable salt, which is useful for treatment or prophylaxis of diseases associated with URAT1 such as gout, hyperuricemia, hypertension, kidney diseases such as interstitial nephritis, diabetes, arteriosclerosis and Lesch-Nyhan syndrome.

The invention belongs to the field of medicinal chemistry and particularly relates to hURAT1 (human urate anion transporter 1) inhibitors and an application thereof. Specifically, the hURAT1 inhibitors are compounds with structure shown as formula (I) or (II) in the description or pharmaceutically acceptable salts of the compounds. Experiments prove that the compounds have good inhibition effect on uric acid transport of the hURAT1 in an HEK293 transfection cell, which shows that the compounds have good application prospect in treatment of hyperuricemia or gout.

The present invention is directed to certain novel triazole compounds represented by Formula I and pharmaceutically acceptable salts, solvates, hydrates, and prodrugs thereof. The present invention is also directed to methods of making and using such compounds and pharmaceutical compositions containing such compounds to treat or control a number of diseases mediated by PPAR such as glucose metabolism, lipid metabolism and insulin secretion, specifically Type 2 diabetes, hyperinsulemia, hyperlipidemia, hyperuricemia, hypercholesteremia, atherosclerosis, one or more risk factors for cardiovascular disease, Syndrome X, hypertriglyceridemia, hyperglycemia, obesity, and eating disorders.

The invention relates to a drug for treating purine metabolic disorder disease, provides a flavonoids compound represented by the formula (I) and a modified derivative thereof, and a use in inhibition of xanthine oxidase activity and promotion of uric acid excretion function, wherein R1, R2 and R3 independently represent -H or monosaccharide residues, and R4 represents -H or -OH. In particular, the drug is used for treating purine metabolic disorder disease, and can be used for treating hyperuricemia and related diseases and reducing a individual serum UA level; the drug is used for treating hyperuricemia; the drug is used for treating the related diseases, such as for treating gouty arthritis and arthrophlogosis caused by hyperuricemia, and for treating chronic interstitial nephritis, kidney stones and the like caused by hyperuricemia. The drug has the advantages of natural chemical structure, safety, low toxicity, rapid curative effect and fewer side effects. (I).

The invention discloses novel medicinal application of coreopsis tinctoria, and particularly relates to application of coreopsis tinctoria extract to preparing medicines for treating hyperuricemia. The novel medicinal application has the advantages that effects of treating the hyperuricemia can be realized by the coreopsis tinctoria extract, the concentration of uric acid in blood can be effectively reduced, and excellent curative effects can be realized for metabolic diseases such as acute gout, chronic gout, gouty arthritis, gout flare, uric acid renal lithiasis and gouty nephropathy which are relevant to the hyperuricemia.

The present invention is directed to certain novel triazole compounds represented by Formula I and pharmaceutically acceptable salts, solvates, hydrates, and prodrugs thereof. The present invention is also directed to methods of making and using such compounds and pharmaceutical compositions containing such compounds to treat or control a number of diseases mediated by PPAR such as glucose metabolism, lipid metabolism and insulin secretion, specifically Type 2 diabetes, hyperinsulemia, hyperlipidemia, hyperuricemia, hypercholesteremia, atherosclerosis, one or more risk factors for cardiovascular disease, Syndrome X, hypertriglyceridemia, hyperglycemia, obesity, and eating disorders.

Methods and compositions for treating and / or preventing hyperuricemia or metabolic disorders associated with hyperuricemia comprising administering to a patient in need a therapeutically effective amount of diacerein, rhein, or a pharmaceutically acceptable salt, an analog, a prodrug, or an active metabolite thereof.

The invention discloses an application of a folium eucalypti extractive serving as an active ingredient in preparation of medicines for treating hyperuricemia, and also provides a preparation method of the folium eucalypti extractive. Main active ingredients of the folium eucalypti extractive are 6-12% of scabish essence B, 1-2% of tellimagrandin I, 1-1.5% of quercetin-3-O-glucoside acid, 0.8-1.2% of ellagic acid, 0.2-0.5% of tellimagrandin II, 0.1-0.15% of 1,2,3,4,6 pentagalloylglucose and 25-50% of total phenols. The pharmacological experiment shows that the folium eucalypti extractive has an inhibiting effect on xanthine oxidase and relatively strong effects of reducing uric acid, protecting renal injury caused by the hyperuricemia and the like in bodies.

The invention relates to a resveratrol tetramer compound and its preparation method. The preparation method comprises: (1) subjecting the twigs of dipterocarpus alatus to alcohol extraction for preparing extract, (2) conducting sample loading by a dry method, (3) carrying out elution with mobile phase eluent, and (4) performing gel column chromatography. The invention also relates to application of the resveratrol tetramer compound in medicaments for preventing or treating hyperuricemia and gout or in health food. The extraction and purification process of the resveratrol tetramer compound provided in the invention dose not employ a reversed phase and a semi-preparative column, so that the technology has simple process and high yield. In addition, compared with inventions directed at gout and hyperuricemia, the resveratrol tetramer compound of the invention is a monomeric compound, which, as a natural uric acid lowering agent, has clear effective components and an obvious uric acid lowering effect. Being able to serve as a quality standard, the compound of the invention is convenient and reliable, thus providing a scientific basis for its clinical application.

The invention provides a composition and application of the composition in the preparation of medicaments, health-care food or functional food for preventing and treating hyperuricemia. The composition comprises at least one of holothuria saponins and holothuria polysaccharides, wherein the holothuria saponins are main secondary metabolites in holothuria, and have various physiological and pharmacological activity of hemolysis, fungus resistance, cytotoxicity, tumor resistance, immunoregulation, antioxidation, blood fat reduction and the like and have high medicinal value; the holothuria polysaccharides are important ingredients of holothuria body walls, and have the pharmacological activity of anticoagulation, thrombus resistance, tumor resistance, immunoregulation and the like. Animal experiments prove that the prepared composition containing at least one of the holothuria saponins and the holothuria polysaccharides can improve the serum uric acid level of animals in vivo obviously so as to prevent and treat the hyperuricemia.

The invention discloses application of Gynura procumbens to the production of medicine, healthcare food or functional food for preventing and treating hyperuricemia. Evidence is provided to show that the Gynura procumbens has an evident effect of preventing and treating the hyperuricemia, can lower the serum uric acid value of a patient with the hyperuricemia, has an evident uric acid lowering effect and is capable of relieving the clinical symptoms of the patient with the hyperuricemia.

The invention belongs to the chemical field of natural products and in particular relates to an extraction method and an application of moringa oleifera leaf total flavones. The extraction method adopts microwave and ultrasound to synergistically extract the moringa oleifera leaf total flavones, and has the advantages of high efficiency, time saving, energy conservation, low energy consumption, simple operation and good repeatability. Besides, an animal test proves that the extracted moringa oleifera leaf total flavones have a significant treatment effect on hyperuricosuria and Alzheimer's disease. The total flavones provided by the invention can reduce uric acid, and can also reduce cholesterol, triacylglycerol, urea nitrogen, creatinine and xanthine oxidase, reduce the generation of uric acid, directly decompose uric acid, improve the renal function, promote uric acid excretion, and protect multiple levels of blood vessels to reduce uric acid, so that the moringa oleifera leaf total flavones are beneficial for healing of lithemia patients and have a broad medical application prospect.

The invention discloses a plant composition for treating hyperuricemia and gout and plant composition solid granules. The plant composition is prepared from celery seed extract, corn silk powder, pumpkin powder, lotus leaf powder, mulberry powder, ginseng powder grape powder by mixing. The plant composition solid granules are mainly prepared from the plant composition. According to the plant composition for treating the hyperuricemia and the gout and the plant composition solid granules, the celery seed extract, the corn silk powder, the pumpkin powder, the lotus leaf powder, the mulberry powder, the ginseng powder and the grape powder are compounded for use to improve the nutritional compositions, and the celery seed extract can significantly reduce the serum uric acid level and the urineuric acid level of the hyperuricemia; the corn silk powder and the lotus leaf powder can accelerate urinary excretion and help uric acid excretion; and the pumpkin powder, the mulberry powder, the ginseng powder and the grape powder have the functions of nourishing the liver and kidney, enhancing immunity and protecting the liver and kidney. The action mechanism of each component is different, multi-component mixing effectively exerts the synergistic effect between the components, the action time is prolonged, the curative effect is enhanced, and the components are homologous to medicine andfood, are safe and have no side effects.

Methods and compositions for treating and / or preventing hyperuricemia or metabolic disorders associated with hyperuricemia comprising administering to a patient in need a therapeutically effective amount of diacerein, rhein, or a pharmaceutically acceptable salt, an analog, a prodrug, or an active metabolite thereof.

The invention discloses a preparation method of marine oligopeptide with uric acid reducing activity, and relates to the technical field of deep processing of aquatic products. The preparation methodof the oligopeptide comprises the following steps: processed bonito surimi is subjected to enzymolysis by 4400 U / g of flavourzyme for 6.5 h at the temperature of 42 DEG C, freeze-drying is performed after enzymolysis, and the bonito oligopeptide is prepared. The prepared bonito oligopeptide can be used for antagonizing hyperuricemia in mice, reducing toxic and side effects of drug treatment and treatment cost, is good for reducing incidence of chronic diseases such as gout, and has good market prospect.

The present application discloses stable pharmaceutical compositions for the oral administration of febuxostat with pharmaceutical excipients which provide improved dissolution rate and polymorphic stability both while manufacturing and during storage and process for preparing the stable compositions, packaging and their use in the treatment of gout of hyperuricemia.

The invention relates to a composition and application thereof in reduction of uric acid and treatment or prevention of gout. The composition provided by the invention is prepared from quercetin and anserine. The composition can effectively reduce the uric acid and treat hyperuricemia and the gout.

The present invention provides a drug for treating hyperuricemia and gout, ie., evodiamine dispersion tablets. The evodiamine dispersion tablets are the preparation prepared from the following raw materials and additives, by weight, 7-13 parts of evodiamine, 30-50 parts of a solid dispersion water-soluble carrier material, 70-90 parts of a filler, and 8-14 parts of a disintegrating agent. The present invention further provides a preparation method and uses of the dispersion tablets. The evodiamine dispersion tablets of the present invention have characteristics of short disintegration time and high dispersion uniformity. According to the present invention, the dissolution of the insoluble drug evodiamine in the solid preparation can be significantly improved, the absorption of the evodiamine in the human body is prompted, the bioavailability of the drug is increased, and new selections are provided for clinical medication for treatments of hyperuricemia and gout.

The invention relates to a medicine for treating gout, hyperuricemia and hyperlipemia and preparation method thereof, which is prepared from cassia seed, plantain herb, ligustrum japonicum, black-tail snake, wasp's nest, and gynostemma pentaphylla. The invention also relates to the process for preparing various preparations of the medicament.

The invention provides a DNA tetrahedron-resveratrol compound as well as a preparation method and application thereof, and belongs to the technical field of medicines. The compound is a compound formed by mixing DNA tetrahedral framework nucleic acid and resveratrol. The DNA tetrahedron-resveratrol compound can effectively reduce body weight and blood sugar content and improve tolerance to glucose and insulin, so that obesity is effectively treated, and insulin resistance caused by obesity is improved and even treated; the compound can also be used for treating metabolic syndrome, type 2 diabetes mellitus, hypertension, hyperuricemia, dyslipidemia, cardiovascular and cerebrovascular diseases, polycystic ovarian syndrome, Alzheimer's disease or tumor and other diseases caused by insulin resistance. Meanwhile, the compound disclosed by the invention can be used for effectively treating adipose tissue inflammation. Compared with single use of DNA tetrahedral framework nucleic acid or resveratrol, the compound disclosed by the invention plays a synergistic effect and has a good application prospect.

The invention relates to an ampelopsis grossedentata leaf and herba cichorii composition and a preparation method thereof and application of the composition. The ampelopsis grossedentata leaf and herba cichorii composition consists of ampelopsis grossedentata leaves, herba cichorii, fructus gardeniae, folium mori, radix puerariae and bulbus lilii. The composition of the invention takes medicinal and edible medicinal materials as raw materials; according to the theory of traditional Chinese medicine, medicine properties and dosage, the composition is reasonably proportioned, keeps pathogenesis,and performs treatment based on syndrome differentiation, and has a significant treatment effect on damp-heat blockage type uricemia (symptoms including proteinuria, hematuresis, edema, uric acid calculus, glucose and lipid metabolism disorder and the like). In addition, the prescription of the invention has no toxic and side effects, is safe and reliable, and is convenient to take.

The invention relates to a medicine composition for treating hyperuricemia and hyperuricemia related diseases (such as gout, urate nephropathy). The medicine composition is characterized by being prepared by adopting the following traditional Chinese medicine raw material according to the weight proportion: 0.1-15g of artemisia anomala, 0.1-15g of the bark of ash, 0.1-15g of thunberg fritillary bulb, 0.1-30g of wild chrysanthemum flower, 0-30g of astragalus root, 0-15g of cassia twig, 0-15g of kadsura pepper stem, 0-15g of herba lycopi and 0-15g of baical skullcap root. The invention discloses a preparation method, a preparation and application of the medicine composition. The invention has better safety, can effectively lower the concentration of uric acid and remarkably improve the symptoms of all stages of gout, and is suitable for treatment of hyperuricemia related diseases (such as gout, urate nephropathy), especially treatment of gout incubation (hyperuricemia) and diapause.

The invention discloses a hematuria-reducing lactic acid bacteria strain and a screening method and application thereof in preparation of functional yoghourt. The strain is characterized in that the lactic acid bacteria strain is classified and named as Lactobacillus brevis PDD-5 strain, is preserved in China General Microbiological Culture Collection Center on August 31, 2020, and has a preservation number of CGMCC No. 20573. The screening method comprises the following steps of (1), selecting traditional fermented food pickles as samples, and carrying out preliminary screening and separationpurification on lactic acid bacteria; and (2), obtaining strains with negative catalase activity and positive gram staining, then culturing and collecting thalli, re-suspending the thalli in an inosine guanosine solution and culturing, and then selecting lactic acid bacteria with the highest degradation rate on inosine or guanosine. The method has the advantages of oxidation resistance, inflammation resistance, immunoregulation, blood uric acid reduction, capability of relieving and treating hyperuricemia and the like.

The invention discloses an application of Bacillus coagulans in the preparation of a blood uric acid lowering preparation. The application is concretely characterized in that the Bacillus coagulans isused to lower the blood uric acid and prevent or treat hyperuricemia, gout and gout complications.